United States In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
NEW YORK, Jan. 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0763017/United-States-In-Vitro-Diagnostics-Market-Outlook-to-2017---Clinical-Chemistry-Genetic-Testing-Haematology-Histology-and-Cytology-Immuno-Chemistry-Infectious-Immunology-and-Microbiology-Culture.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic
United States In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
Summary
GlobalData's new report, "United States In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" provides key market data on the United States In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
- 2010 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the United States In Vitro Diagnosticsmarket.
- Key players covered include Abbott Laboratories, Siemens Healthcare, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the United States In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 12
2 Introduction 15
2.1 What is This Report About? 15
3 In Vitro Diagnostics In United States 16
3.1 In Vitro Diagnostics, Market Segmentation 16
3.2 In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017 17
3.3 In Vitro Diagnostics Market, United States, Revenue Mix ($m), 2010 19
3.4 In Vitro Diagnostics Market, United States, Category Contribution (%), 2010 20
3.5 In Vitro Diagnostics, United States, Company share (2009-2010) 27
4 Clinical Chemistry In United States 29
4.1 Clinical Chemistry, Market Segmentation 29
4.2 Clinical Chemistry Market, United States, Revenue Mix ($m), 2010 30
4.3 Clinical Chemistry Market, United States, Segment Contribution (%), 2010 31
4.4 Clinical Chemistry Overall Revenue (2003-2017) 32
4.5 Clinical Chemistry Distribution Share (2009-2010) 44
4.6 Clinical Chemistry, United States, Company share (2009-2010) 45
5 Genetic Testing In United States 47
5.1 Genetic Testing, Market Segmentation 47
5.2 Genetic Testing Market, United States, Revenue Mix ($m), 2010 48
5.3 Genetic Testing Market, United States, Segment Contribution (%), 2010 49
5.4 Genetic Testing Overall Revenue (2003-2017) 50
5.5 Genetic Testing Distribution Share (2009-2010) 54
5.6 Genetic Testing, United States, Company share (2009-2010) 55
6 Haematology In United States 57
6.1 Haematology, Market Segmentation 57
6.2 Haematology Market, United States, Revenue Mix ($m), 2010 58
6.3 Haematology Market, United States, Segment Contribution (%), 2010 59
6.4 Haematology Overall Revenue (2003-2017) 60
6.5 Haematology Distribution Share (2009-2010) 84
6.6 Haematology, United States, Company share (2009-2010) 85
7 Histology And Cytology In United States 87
7.1 Histology and Cytology, Market Segmentation 87
7.2 Histology And Cytology Market, United States, Revenue Mix ($m), 2010 88
7.3 Histology And Cytology Market, United States, Segment Contribution (%), 2010 89
7.4 Histology And Cytology Overall Revenue (2003-2017) 90
7.5 Histology And Cytology Distribution Share (2009-2010) 94
7.6 Histology And Cytology, United States, Company share (2009-2010) 95
8 Immuno Chemistry In United States 97
8.1 Immuno Chemistry Market, United States, Revenue Mix ($m), 2010 97
8.2 Immuno Chemistry Market, United States, Segment Contribution (%), 2010 98
8.3 Immuno Chemistry Overall Revenue (2003-2017) 100
8.4 Immuno Chemistry Distribution Share (2009-2010) 124
8.5 Immuno Chemistry, United States, Company share (2009-2010) 125
9 Infectious Immunology In United States 127
9.1 Infectious Immunology, Market Segmentation 127
9.2 Infectious Immunology Market, United States, Revenue Mix ($m), 2010 128
9.3 Infectious Immunology Market, United States, Segment Contribution (%), 2010 129
9.4 Infectious Immunology Overall Revenue (2003-2017) 130
9.5 Infectious Immunology Distribution Share (2009-2010) 134
9.6 Infectious Immunology, United States, Company share (2009-2010) 135
10 Microbiology Culture In United States 137
10.1 Microbiology Culture, Market Segmentation 137
10.2 Microbiology Culture Market, United States, Revenue Mix ($m), 2010 138
10.3 Microbiology Culture Market, United States, Segment Contribution (%), 2010 139
10.4 Microbiology Culture Overall Revenue (2003-2017) 140
10.5 Microbiology Culture Distribution Share (2009-2010) 148
10.6 Microbiology Culture, United States, Company share (2009-2010) 149
11 Overview of Key Companies in United States In Vitro Diagnostics Market 151
11.1 Abbott Laboratories 151
11.2 Siemens Healthcare 152
11.3 F. Hoffmann-La Roche Ltd. 153
11.4 Beckman Coulter, Inc. 154
11.5 Ortho-Clinical Diagnostics Inc. 155
11.6 bioMerieux S.A. 156
11.7 Becton, Dickinson and Company 157
11.8 Bio-Rad Laboratories, Inc. 157
11.9 Alere Inc. 157
11.10 Sysmex Corporation 158
11.11 Qiagen N.V. 158
11.12 Gen-Probe Incorporated 158
11.13 DiaSorin S.p.A 159
11.14 Thermo Fisher Scientific Inc. 159
11.15 Immucor, Inc. 160
11.16 Hologic, Inc. 160
11.17 Phadia AB 160
11.18 Cepheid 161
11.19 Grifols, S.A. 161
11.20 Life Technologies Corporation 162
11.21 PerkinElmer, Inc. 162
11.22 HORIBA, Ltd. 163
11.23 OraSure Technologies, Inc. 163
11.24 Danaher Corporation 163
11.25 Abbott Laboratories 164
12 In Vitro Diagnostics Market Pipeline Products 165
12.1 Clinical Chemisty Market Pipeline Products 165
12.2 Immuno Chemistry Market Pipeline Products 168
12.3 Haematology Market Pipeline Products 171
12.4 Infectious Immunology Market Pipeline Products 174
12.5 Microbiology Culture Market Pipeline Products 177
12.6 Histology and Cytology Market Pipeline Products 179
12.7 Genetic Testing Market Pipeline Products 180
13 Financial Deals Landscape 183
13.1 Merger 183
13.2 Acquisition 185
13.3 Partnerships 237
14 Recent Developments 322
14.1 Strategy and Business Planning 322
14.2 Legal and Regulatory 340
14.3 Government and Public Interest 348
14.4 Product News 415
15 Appendix 491
15.1 Definitions of Markets Covered in the Report 492
15.2 Research Methodology 502
15.3 Secondary Research 502
15.4 Primary Research 503
15.5 Models 503
15.6 Forecasts 504
15.7 Expert Panels 504
15.8 GlobalData Consulting 504
15.9 Contact Us 505
15.10 Disclaimer 505
List of Tables
Table 1: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017 33
Table 2: In Vitro Diagnostics Market, United States, Category Contribution (%), 2010 35
Table 3: In Vitro Diagnostics, United States, Cross-Category Analysis, 2003-2017 37
Table 4: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Historic, 2003-2010 39
Table 5: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 41
Table 6: In Vitro Diagnostics, United States, Company share by Revenue ($m), USD Actual, 2009-2010 43
Table 7: Clinical Chemistry Market, United States, Segment Contribution (%), 2010 46
Table 8: Clinical Chemistry, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 48
Table 9: Clinical Chemistry, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 50
Table 10: Clinical Chemisty Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 52
Table 11: Clinical Chemisty Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 54
Table 12: Urine Analysis, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 56
Table 13: Urine Analysis, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 58
Table 14: Clinical Chemistry, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010 59
Table 15: Clinical Chemistry, United States, Company share by Revenue ($m), USD Actual 2009-2010 61
Table 16: Genetic Testing Market, United States, Segment Contribution (%), 2010 64
Table 17: Genetic Testing, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 66
Table 18: Genetic Testing, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 68
Table 19: Genetic Testing, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010 69
Table 20: Genetic Testing, United States, Company share by Revenue ($m), USD Actual 2009-2010 71
Table 21: Haematology Market, United States, Segment Contribution (%), 2010 74
Table 22: Haematology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 76
Table 23: Haematology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 78
Table 24: Haematology Reagents, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 80
Table 25: Haematology Reagents, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 82
Table 26: Immunohaematology, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 84
Table 27: Immunohaematology, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 86
Table 28: Haemostasis, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 88
Table 29: Haemostasis, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 90
Table 30: Haematology Rapid Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 92
Table 31: Haematology Rapid Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 94
Table 32: Haematology Cell Counters, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 96
Table 33: Haematology Cell Counters, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 98
Table 34: Haematology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010 99
Table 35: Haematology, United States, Company share by Revenue ($m), USD Actual 2009-2010 101
Table 36: Histology And Cytology Market, United States, Segment Contribution (%), 2010 104
Table 37: Histology And Cytology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 106
Table 38: Histology And Cytology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 108
Table 39: Histology And Cytology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010 109
Table 40: Histology And Cytology, United States, Company share by Revenue ($m), USD Actual 2009-2010 111
Table 41: Immuno Chemistry Market, United States, Segment Contribution (%), 2010 114
Table 42: Immuno Chemistry, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 116
Table 43: Immuno Chemistry, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 118
Table 44: Disease Specific Immunochemistry, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 120
Table 45: Disease Specific Immunochemistry, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 122
Table 46: Drugs of Abuse / Toxicology, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 124
Table 47: Drugs of Abuse / Toxicology, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 126
Table 48: Endocrinology Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 128
Table 49: Endocrinology Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 130
Table 50: Therapeutic Drug Monitoring, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 132
Table 51: Therapeutic Drug Monitoring, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 134
Table 52: Immunochemistry Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 136
Table 53: Immunochemistry Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 138
Table 54: Immuno Chemistry, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010 139
Table 55: Immuno Chemistry, United States, Company share by Revenue ($m), USD Actual 2009-2010 141
Table 56: Infectious Immunology Market, United States, Segment Contribution (%), 2010 144
Table 57: Infectious Immunology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 146
Table 58: Infectious Immunology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 148
Table 59: Infectious Immunology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010 149
Table 60: Infectious Immunology, United States, Company share by Revenue ($m), USD Actual 2009-2010 151
Table 61: Microbiology Culture Market, United States, Segment Contribution (%), 2010 154
Table 62: Microbiology Culture, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 156
Table 63: Microbiology Culture, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 158
Table 64: Microbiology Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 160
Table 65: Microbiology Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 162
Table 66: Microbiology Culture, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010 163
Table 67: Microbiology Culture, United States, Company share by Revenue ($m), USD Actual 2009-2010 165
Table 68: Clinical Chemisty Market Pipeline Products 180
Table 69: Immuno Chemistry Market Pipeline Products 183
Table 70: Haematology Market Pipeline Products 186
Table 71: Infectious Immunology Market Pipeline Products 189
Table 72: Microbiology Culture Market Pipeline Products 192
Table 73: Histology and Cytology Market Pipeline Products 194
Table 74: Genetic Testing Market Pipeline Products 195
Table 75: Transonic Systems Merges With Scisense 198
Table 76: Vivakor Enters Into Memorandum Of Understanding To Merge With Resolution Biomedical 199
Table 77: Pall Corporation To Acquire ForteBio 200
Table 78: Shionogi Acquires Remaining 13% Joint Venture Stake In Ezose Sciences 202
Table 79: Agilent Technologies Completes Acquisition Of BioSystem Development 203
Table 80: Affymetrix To Acquire eBioscience For $330 Million 204
Table 81: AMAG Pharmaceuticals Plans For Sale Of The Company 206
Table 82: Vermillion Completes Acquisition Of Correlogic Systems For $0.4 Million 207
Table 83: Evonik Industries Acquires SurModics Pharmaceuticals From SurModics For $30 Million 209
Table 84: Everist Genomics Acquires Angiologix 211
Table 85: WuXi PharmaTech Acquires Abgent 212
Table 86: OPKO Health Acquires Claros Diagnostics 214
Table 87: Miraca Holdings Completes Acquisition Of Caris Diagnostics From Caris Life Sciences For $725 Million 216
Table 88: Bio-Rad Laboratories Acquires QuantaLife For $162 Million 218
Table 89: Sony Corporation of America Acquires Micronics 219
Table 90: PerkinElmer Completes Acquisition Of Caliper Life Sciences For $600 Million 220
Table 91: Thermo Fisher Scientific Acquires Intrinsic Bioprobes 222
Table 92: EMD Millipore To Acquire Amnis 223
Table 93: Thermo Fisher Scientific Acquires TREK Diagnostic Systems 224
Table 94: Solstas Lab Partners Acquires NextWave Diagnostic Laboratories 226
Table 95: Solstas Lab Partners Acquires Wilmington Pathology Laboratory 227
Table 96: Signal Genetics Acquires DiagnoCure Oncology Laboratories 228
Table 97: Luminex Completes Acquisition Of EraGen Biosciences 229
Table 98: Solstas Lab Partners Acquires Select Diagnostics 231
Table 99: BioMedical Technology Solutions Holdings To Acquire SharpsMD And 2000 Plus Consulting 232
Table 100: Nestle Health Science Completes Acquisition Of Prometheus Laboratories 234
Table 101: Abcam Acquires MitoSciences 236
Table 102: Health Diagnostic Laboratory Acquires Harris Scientific 238
Table 103: EKF Diagnostics Completes Acquisition of Stanbio Laboratory 239
Table 104: PositiveID Completes Acquisition Of MicroFluidic Systems 240
Table 105: Navitar Life Sciences To Acquire Modulation Optics 242
Table 106: Myriad Genetics Acquires Rules-Based Medicine 243
Table 107: Shrink Nanotechnologies To Acquire Nanopoint 245
Table 108: Novelos Therapeutics Acquires Cellectar 247
Table 109: LabCorp Completes Acquisition Of Orchid Cellmark For $85 Million 249
Table 110: HistoRx Enters Into Licensing Agreement With Yale University 252
Table 111: BioTime Enters Into Distribution Agreement With USCN Life Science 253
Table 112: Critical Path Institute Signs Memorandum Of Understanding With The Hamner Institutes 254
Table 113: Tyrian Diagnostics Enters Into Distribution Agreement With NeoClone 255
Table 114: Global BioDiagnostics Extends Co-Development Agreement With Foundation for Innovative New Diagnostics 256
Table 115: Lineagen Enters Into Co-Development Agreement With Fast Forward 257
Table 116: Pathogenetix Enters Into Co-Development Agreement With Sagentia 258
Table 117: Bio-Rad Expands Co-Marketing Agreement With Siemens Medical 259
Table 118: Ezose Sciences Enters Into Co-Development Agreement With Merck 260
Table 119: Fluxion Biosciences Enters Into Distribution Agreement With EMD Millipore 261
Table 120: Roche Enters Into Technology Integration Agreement With Labcyte 262
Table 121: Sony DADC BioSciences Enters Into Co-Development Agreement With Maven Biotechnologies 263
Table 122: Abbott Laboratories Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals 264
Table 123: Olink Bioscience Enters Into Distribution Agreement With Bethyl Laboratories 265
Table 124: SuperNova Diagnostics Enters Into Co-Development Agreement With Concile 266
Table 125: OncoSec Medical Enters Into Research Agreement With Serametrix 267
Table 126: Bruker Enters Into Co-Development Agreement With Lawrence Berkeley National Laboratory 268
Table 127: Dako Enters Into Co-Development Agreement With Bristol-Myers 270
Table 128: Transgenomic Enters Into Distribution Agreement With ScreenCell 271
Table 129: Horizon Discovery Enters Into Co-Development Agreement With Promega 272
Table 130: Stemina Biomarker Discovery Enters Into Co-Development Agreement With ILS 273
Table 131: Psyche Systems Enters Into Technology Integration Agreement With Aperio Technologies 274
Table 132: Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals 275
Table 133: PrognosDx Health Entetrs Into Co-Development Agreement With Accium BioSciences 276
Table 134: The Molecular Sciences Forms Joint Venture With VTT Technical Research 277
Table 135: DxTerity Diagnostics Enters Into Technology Integration Agreement With Caliper Life Sciences 278
Table 136: Gold Standard Diagnostics Extends Distribution Agreement With Fujirebio Diagnostics 279
Table 137: New England Biolabs Enters Into Co-Marketing Agreement With Rubicon Genomics 280
Table 138: WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics 281
Table 139: Illumina Enters Into Co-Development Agreement With University Of North Texas Health Science Center 282
Table 140: Absorption Systems Enters Into Co-Development Agreement With Temple University And Washington State University 283
Table 141: Oasis Diagnostics Enters Into Licensing Agreement With Two Researchers 284
Table 142: Bioo Scientific Enters Into Co-Development Agreement With JungWoo 285
Table 143: Accelr8 Technology Amends Licensing Agreement With SCHOTT 286
Table 144: Orion Genomics Enters Into Licensing Agreement With QIAGEN 287
Table 145: Quantum Materials Enters Into Technology Integration Agreement With Nanoaxis 288
Table 146: RedHill Biopharma Enters Into Licensing Agreement With UCF Research Foundation 289
Table 147: SuviCa Enters Into Licensing Agreement With University of Colorado 290
Table 148: Polymedco Enters Into Distribution Agreement With Cardinal Health 291
Table 149: Universal Biosensors Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics 292
Table 150: LI-COR Biosciences Enters Into Licensing Agreement With Johns Hopkins University 293
Table 151: QIAGEN Enters Into Co-Development Agreement With Eli Lilly 294
Table 152: Sun Yat-sen University Enters Into Co-Development Agreement With BioDesign Institute 295
Table 153: Lumora Enters Into Licensing Agreement With 3M 296
Table 154: NuGEN Technologies Enters Into Co-Development Agreement With Advanced Liquid Logic And Broad Institute 297
Table 155: Biocept Enters Into Co-Marketing Agreement With Clarient 299
Table 156: Quanterix Enters Into Co-Development Agreement With STRATEC Biomedical 300
Table 157: DNA Diagnostics Center Enters Into Licensing Agreement 302
Table 158: Pronexus Enters Into Technology Integration Agreement With RealityCorp 303
Table 159: Carl Zeiss Enters Into Licensing Agreement With Prior Scientific 304
Table 160: EPIC Enters Into Distribution Agreement With Micro Imaging Technology 305
Table 161: BD Diagnostics Enters Into Co-Development Agreement With Lab21 306
Table 162: Procognia Enters Into Co-Development Agreement With Caerus Discovery 307
Table 163: BioMarCare Technologies Enters Into Co-Development Agreement With Ariadne 308
Table 164: Hycor Biomedical Signs Licensing Agreement With Axis-Shield 309
Table 165: Thermo Fisher Scientific Enters Into Licensing Agreement With Alere 310
Table 166: Quanterix Enters Into Co-Development Agreement With Sony DADC 311
Table 167: Canon U.S. Life Sciences Enters Into Co-Development Agreement With The University of Maryland 312
Table 168: Mayo Medical Laboratories Enters Into Licensing Agreement With Qiagen 313
Table 169: Rhoen-Klinikum Enters Into Co-Development Agreement With Siemens 314
Table 170: Proteome Sciences Enters Into Collaboration With Buck Institute 315
Table 171: Stratos Product Development Enters Into Co-Development Agreement With Response Biomedical 316
Table 172: Gold Standard Diagnostics Enters Into Distribution Agreement With Fujirebio Diagnostics 317
Table 173: Roche NimbleGen Enters Into Co-Marketing Agreement With Caliper Life Sciences 318
Table 174: Clinical Genomics Extends Its Licensing Agreement With Quest Diagnostics 319
Table 175: LaserGen Enters Into Co-Development Agreement With National Instruments 320
Table 176: Proteome Sciences Enters Into Co-Development Agreement With H. Lee Moffitt Cancer Center 321
Table 177: Metamark Genetics Enters Into Co-Development Agreement With Definiens 322
Table 178: Allegro Diagnostics Enters Into Licensing Agreement With Boston University And The University of Utah 323
Table 179: Signal Genetics Enters Into Research And Development Agreement With DiagnoCure 324
Table 180: Atherotech Diagnostics Enters Into Co-Marketing Agreement With GlycoMark 325
Table 181: Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 326
Table 182: Mayo Clinic Enters Into Licensing Agreement With Rheonix 328
Table 183: ResearchDx Enters Into Partnership With CompanDX 329
Table 184: Enzo Clinical Enters Into Co-Marketing Agreement With IncellDx 330
Table 185: Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina 331
Table 186: F. Hoffmann-La Roche Enters Into Co-Development Agreement With Merck 332
Table 187: Pivotal Therapeutics Enters Into Co-Marketing Agreement With Nutrasource Diagnostics 333
Table 188: Roche Enters Into Co-Development Agreement With Clovis Oncology 334
Table 189: Molecular Response Enters Into An Agreement With Scripps Translational Science Institute 335
Table 190: SAIC-Frederick Enters Into An Agreement With Biomatrica 336
List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation 31
Figure 2: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017 32
Figure 3: In Vitro Diagnostics Market, United States, Revenue Mix ($m), 2010 34
Figure 4: In Vitro Diagnostics Market, United States, Category Contribution (%), 2010 35
Figure 5: In Vitro Diagnostics, United States, Cross-Category Analysis, 2003-2017 36
Figure 6: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Historic, 2003-2010 38
Figure 7: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 40
Figure 8: In Vitro Diagnostics, United States, Company share (%), 2010 42
Figure 9: Clinical Chemistry, Market Segmentation 44
Figure 10: Clinical Chemistry Market, United States, Revenue Mix ($m), 2010 45
Figure 11: Clinical Chemistry Market, United States, Segment Contribution (%), 2010 46
Figure 12: Clinical Chemistry, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 47
Figure 13: Clinical Chemistry, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 49
Figure 14: Clinical Chemisty Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 51
Figure 15: Clinical Chemisty Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 53
Figure 16: Urine Analysis, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 55
Figure 17: Urine Analysis, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 57
Figure 18: Clinical Chemistry, United States, Company share (%), 2010 60
Figure 19: Genetic Testing, Market Segmentation 62
Figure 20: Genetic Testing Market, United States, Revenue Mix ($m), 2010 63
Figure 21: Genetic Testing Market, United States, Segment Contribution (%), 2010 64
Figure 22: Genetic Testing, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 65
Figure 23: Genetic Testing, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 67
Figure 24: Genetic Testing, United States, Company share (%), 2010 70
Figure 25: Haematology, Market Segmentation 72
Figure 26: Haematology Market, United States, Revenue Mix ($m), 2010 73
Figure 27: Haematology Market, United States, Segment Contribution (%), 2010 74
Figure 28: Haematology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 75
Figure 29: Haematology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 77
Figure 30: Haematology Reagents, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 79
Figure 31: Haematology Reagents, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 81
Figure 32: Immunohaematology, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 83
Figure 33: Immunohaematology, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 85
Figure 34: Haemostasis, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 87
Figure 35: Haemostasis, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 89
Figure 36: Haematology Rapid Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 91
Figure 37: Haematology Rapid Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 93
Figure 38: Haematology Cell Counters, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 95
Figure 39: Haematology Cell Counters, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 97
Figure 40: Haematology, United States, Company share (%), 2010 100
Figure 41: Histology and Cytology, Market Segmentation 102
Figure 42: Histology And Cytology Market, United States, Revenue Mix ($m), 2010 103
Figure 43: Histology And Cytology Market, United States, Segment Contribution (%), 2010 104
Figure 44: Histology And Cytology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 105
Figure 45: Histology And Cytology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 107
Figure 46: Histology And Cytology, United States, Company share (%), 2010 110
Figure 47: Immuno Chemistry Market, United States, Revenue Mix ($m), 2010 112
Figure 48: Immuno Chemistry Market, United States, Segment Contribution (%), 2010 113
Figure 49: Immuno Chemistry, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 115
Figure 50: Immuno Chemistry, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 117
Figure 51: Disease Specific Immunochemistry, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 119
Figure 52: Disease Specific Immunochemistry, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 121
Figure 53: Drugs of Abuse / Toxicology, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 123
Figure 54: Drugs of Abuse / Toxicology, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 125
Figure 55: Endocrinology Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 127
Figure 56: Endocrinology Tests, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 129
Figure 57: Therapeutic Drug Monitoring, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 131
Figure 58: Therapeutic Drug Monitoring, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 133
Figure 59: Immunochemistry Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 135
Figure 60: Immunochemistry Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 137
Figure 61: Immuno Chemistry, United States, Company share (%), 2010 140
Figure 62: Infectious Immunology, Market Segmentation 142
Figure 63: Infectious Immunology Market, United States, Revenue Mix ($m), 2010 143
Figure 64: Infectious Immunology Market, United States, Segment Contribution (%), 2010 144
Figure 65: Infectious Immunology, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 145
Figure 66: Infectious Immunology, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 147
Figure 67: Infectious Immunology, United States, Company share (%), 2010 150
Figure 68: Microbiology Culture, Market Segmentation 152
Figure 69: Microbiology Culture Market, United States, Revenue Mix ($m), 2010 153
Figure 70: Microbiology Culture Market, United States, Segment Contribution (%), 2010 154
Figure 71: Microbiology Culture, United States, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 155
Figure 72: Microbiology Culture, United States, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 157
Figure 73: Microbiology Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 159
Figure 74: Microbiology Analyzers, United States, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 161
Figure 75: Microbiology Culture, United States, Company share (%), 2010 164
Figure 76: Abbott Laboratories, Company Share (%),United States In Vitro Diagnostics Market, 2010 166
Figure 77: Siemens Healthcare, Company Share (%),United States In Vitro Diagnostics Market, 2010 167
Figure 78: F. Hoffmann-La Roche Ltd., Company Share (%),United States In Vitro Diagnostics Market, 2010 168
Figure 79: Beckman Coulter, Inc., Company Share (%),United States In Vitro Diagnostics Market, 2010 169
Figure 80: Ortho-Clinical Diagnostics Inc., Company Share (%),United States In Vitro Diagnostics Market, 2010 170
Figure 81: bioMerieux S.A., Company Share (%),United States In Vitro Diagnostics Market, 2010 171
Companies mentioned
Abbott Laboratories
Siemens Healthcare
F. Hoffmann-La Roche Ltd.
Beckman Coulter, Inc.
Ortho-Clinical Diagnostics Inc.
bioMerieux S.A.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Alere Inc.
Sysmex Corporation
Qiagen N.V.
Gen-Probe Incorporated
DiaSorin S.p.A
Thermo Fisher Scientific Inc.
Immucor, Inc.
Hologic, Inc.
Phadia AB
Cepheid
Grifols, S.A.
Life Technologies Corporation
PerkinElmer, Inc.
HORIBA, Ltd.
OraSure Technologies, Inc.
Danaher Corporation
Abbott Laboratories
To order this report:
In Vitro Diagnostic Industry: United States In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article